A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

American Journal of Gastroenterology

Volumn 100, Issue 5, 2005, Pages 1082-1090

  Bugianesi, Elisabetta ^b   Gentilcore, Elena ^b   Manini, Rita ^b   Natale, Stefania ^b   Vanni, Ester ^b   Villanova, Nicola ^b   David, Ezio ^b   Rizzetto, Mario ^b   Marchesini, Giulio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; ANTIOXIDANT; INSULIN; LIVER ENZYME; METFORMIN; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG SAFETY; FEMALE; HEPATITIS; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUTRITION; NUTRITIONAL COUNSELING; NUTRITIONAL THERAPY; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION; AGED; BIOPSY; BLOOD; BODY MASS; COMPARATIVE STUDY; FATTY LIVER; FOLLOW UP; LIVER CIRRHOSIS; LOW CALORY DIET; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BIOPSY; BODY MASS INDEX; DIET, REDUCING; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HEPATITIS; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME; VITAMIN E;

EID: 19144365586     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41583.x     Document Type: Article

References (36)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003;37:1202-19.
2. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
3. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
4. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
5. Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-9.
6. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7.
7. Hickman IE, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-9.
8. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.
9. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44.
10. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. Aliment Pharmacol Ther 2004;20:23-8.
11. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
12. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
13. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
14. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38:434-40.
15. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000;136:734-8.
16. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90.
17. Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: A randomized study. J Pediatr Gastroenterol Nutr 2004;38:48-55.
18. Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: Duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 2003;98:2348-50.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
20. World Health Organization. Preventing and managing the global epidemic: Report of a WHO consultation. WHO technical report series. Geneva: World Health Organization, 2000:1-253.
21. Kris-Etherton P, Eckel RH, Howard BV, et al. AHA science advisory: Lyon diet heart study. Benefits of a Mediterranean-style, national cholesterol education program/American heart association step I dietary pattern on cardiovascular disease. Circulation 2001;103:1823-5.
22. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver-an additional and treatable feature of the insulin resistance syndrome. Q J Med 1999;92:73-9.
23. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
24. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
25. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
26. Magalotti D, Marchesini G, Ramilli S, et al. Splanchnic haemodynamics in non-alcoholic fatty liver disease: Effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis 2004;36:406-11.
27. Hasegawa T, Yoneda M, Nakamura K. et al. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001;15:1667-72.
28. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
29. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54.
30. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
31. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-76.
32. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
33. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76.
34. Maison P, Byrne CD, Hales CN, et al. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001;24:1758-63.
35. Anderson PJ, Critchley JA, Chan JC, et al. Factor analysis of the metabolic syndrome: Obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 2001;25:1782-8.
36. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-50.